No abstract available.
Miller Fisher Syndrome

No abstract available.
Miller Fisher Syndrome*

No abstract available.
Blinking* ; Diplopia ; Miller Fisher Syndrome*

Introduction: Miller Fisher syndrome (MFS) is a variant of Guillain-Barré syndrome (GBS) characterized by an immunemediated polyneuropathy. Diagnosis is largely clinical and spontaneous recovery is observed in most cases. Treatment options such as IVIg, plasmapheresis, and steroids have been studied as options to shorten the disease course, but with inconclusive results. Case: A 25-year-old male complained of sudden onset diplopia, gait instability and hand parasthesia. Diagnosis of MFS was done clinically; chest CT scan, nerve conduction studies, and MRI of brain and orbits were unremarkable. Anti-GQ1b determination was not performed. Low dose oral corticosteroid was initiated with gradual recovery of symptoms noted over two weeks and full recovery in two months. Discussion: Miller Fisher syndrome (MFS) is a rare entity and the least common of the GBS variants. Its incidence as a proportion of GBS accounts for one to five percent in Western countries. Most patients have evidence of an upper respiratory tract infection one to three weeks before symptom onset. MFS is largely considered to be a self-limiting condition, but case series have shown that patients return to normal activities approximately six months after neurological onset. The patient in this report was treated with low dose steroids, with gradual taper over two months. Significant improvement of symptoms was noted over two months, which is shorter than the six months recovery in literature. Conclusion Worldwide incidence of MFS can be underestimated as it is often overlooked during the initial work-up of the disease. The risks of treatment, therefore, should be weighed against the likelihood of spontaneous recovery. Although use of steroids in this case report have noticeably caused a shorter course of the disease, prospective studies are suggested to look into the role of low dose oral corticosteroids in shortening the onset-to-recovery course of this illness.
Miller Fisher Syndrome ; Diplopia ; Steroids

No abstract available.
Gangliosides ; Guillain-Barre Syndrome ; Immunoglobulin G ; Miller Fisher Syndrome

Anti-GQ1 antibody is found in patients with Miller-Fisher syndrome (MFS), atypical MFS, and Bickerstaff's brainstem encephalitis (BBE). These conditions are various manifestations of post-infectious autoimmune disorders, and anti-GQ1b antibodies play a core pathogenic role. So they are referred as the 'anti-GQ1b antibody syndrome'. We report two cases of recurrent anti-GQ1b antibody syndrome.
Antibodies ; Brain Stem ; Encephalitis ; Humans ; Miller Fisher Syndrome ; Recurrence

Miller Fisher syndrome is a syndrome of acute external ophthalmoplegia, ataxia and areflexia without significant motor or sensory deficit in the limbs and usually results in complete recovery without specific treatment. It's accurate anatomic lesion sites and pathogeneiss is still unknown. Recently we experienced a 57 year old man who had the sudden onset of ophthalmoplegia, ataxia, areflexia and albuminocytologic dissociation in CSF and completely recovered 2 1/2 months later.
Ataxia* ; Extremities ; Humans ; Middle Aged ; Miller Fisher Syndrome* ; Ophthalmoplegia

Miller Fisher syndrome is a syndrome of acute external ophthalmoplegia, ataxia and areflexia without significant motor or sensory deficit in the limbs and usually results in complete recovery without specific treatment. It's accurate anatomic lesion sites and pathogeneiss is still unknown. Recently we experienced a 57 year old man who had the sudden onset of ophthalmoplegia, ataxia, areflexia and albuminocytologic dissociation in CSF and completely recovered 2 1/2 months later.
Ataxia* ; Extremities ; Humans ; Middle Aged ; Miller Fisher Syndrome* ; Ophthalmoplegia

Some authors found the anti-GQ1b IgG antibody in some of their patients with acute postinfectious ophthalmoparesis without ataxia, "atypical MFS" or "acute ophthalmoparesis (AO)". Antecedent illness, acute ophthalmoparesis, CSF albuminocytologic dissociation, and the anti-GQ1b IgG antibody are useful markers for diagnosing AO. AO can be considered a variant or atypical form of MFS. We report two monocular AO patients who had the anti-GQ1b IgG antibody along with a literature review.
Ataxia ; Humans ; Immunoglobulin G* ; Miller Fisher Syndrome ; Ophthalmoplegia*

We report on three elderly patients with stroke-like onset of atypical Miller Fisher syndrome (MFS). The serum titer of anti-GQ1b IgG was markedly elevated in these patients. Their prognoses were sufficiently good with immunoadsorption therapy with or without intravenous immune globulin (IVIg) therapy. However, some neurological findings were not characteristic of typical MFS. Patient 1 suffered from prolonged dysesthesia in her left extremities, and Patients 2 and 3 showed no ataxia. Moreover, complete bilateral gaze limitation is rare in MFS. The sudden stroke-like onset along with the gaze limitation of these patients suggests that the unexpected elevation in the serum titer of anti-GQ1b IgG due to unknown immune dysregulation might have severely affected the third, fourth, and sixth nerves and this potent antibody rapidly attacked these nerves and induced stroke-like clinical features and complete ophthalmoplegia.
Cerebrovascular accident ; Miller Fisher Syndrome ; Right and left ; Serum ; Atypical